Assessing Glutamine Metabolism in MGUS and Myeloma

  • End date
    Jun 30, 2024
  • participants needed
  • sponsor
    Mayo Clinic
Updated on 25 March 2022
measurable disease
bone marrow procedure
bone marrow plasma cells


The utilization of glutamine by the bone marrow plasma cells in MGUS and MM will be compared between each other after infusion of 13-carbon labelled glutamine.


Multiple myeloma (MM) is always preceded by a pre-malignant asymptomatic phase, monoclonal gammopathy of undetermined significance (MGUS). Given the incurable nature of MM it is vital to study the development of MM from MGUS to help in identifying early diagnostic and treatment opportunities. This project aims to determine if glutamine metabolism in plasma cells is vital for their survival and whether it is associated with the progression of MGUS to MM. It will involve the utilization of stable isotope resolved metabolomics methods to evaluate the utilization of glutamine by the bone marrow plasma cells in MGUS compared to MM. Patients with MGUS and MM will undergo bone marrow aspirations after being infused with 13-carbon labelled glutamine. The subsequent bone marrow plasma cells obtained from these aspirates will undergo GC-MS assessments of the TCA cycle isotopomers. This will help determine the differences in the utilization of glutamine by the bone marrow plasma cells between MGUS and MM.

Condition Myeloma, MGUS
Treatment Infusion of 13-Carbon labeled Glutamine
Clinical Study IdentifierNCT03119883
SponsorMayo Clinic
Last Modified on25 March 2022


Yes No Not Sure

Inclusion Criteria

IMWG criteria for the diagnosis of either MGUS or MM5
Presence of measurable disease defined by an M-spike of >1 g/dL and/or involved serum free immunoglobulin light chain >10 mg/dL
For MGUS cohort only
At least 5 to <10% cPCs in the prior BM aspirate
Not received any plasma cell directed therapy
For MM cohort
At least >10% cPCs in recent BM aspirate
Newly diagnosed MM without receiving any plasma cell directed therapy OR Relapsed MM without having received salvage chemotherapy

Exclusion Criteria

For both MGUS and MM cohorts
Unable to provide consent
Hemoglobin <10 g/dL
GFR <50 ml/min
Women who are pregnant
Abnormal liver function tests
Abnormal bleeding history or coagulation profile (INR >1.5)
Prior history of adverse events with conscious sedation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note